J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the offering. Beam’s Board of Directors includes CEO John Evans, investors Kristina Burow, Stephen Knight, and Robert Nelsen, co-founder Feng Zhang, and independent director Mark Fishman, M.D., Professor of Stem Cell and Regenerative Biology at Harvard University and formerly the founding President of the Novartis Institutes of BioMedical Research (NIBR). CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of $23.50 per share. Beam Therapeutics's Co-Founder is David R. Liu. All of the shares are being offered by Beam Therapeutics. Nothing contained on the Website shall be considered a recommendation, solicitation, or offer to buy or sell a security to any person in any jurisdiction. +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]-(!![]))+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]))/+((!+[]+(!![])+!![]+!![]+[])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![])+(!+[]-(!![]))+(+!! Headquartered in Cambridge, Massachusetts, the company is backed by F-Prime Capital Partners and ARCH Venture Partners, two of the world’s leading biotech venture capital firms. Wedbush PacGrow is acting as lead manager for the offering. Prior to Genentech, Dr. Ho was on faculty in the Department of Neurology at Stanford University and subsequently a Medical Director at Johnson and Johnson. from Cornell University. Dr. Ho brings to Beam more than 15 years of life sciences experience as a clinical neurologist, neuroscientist and leader in biopharmaceutical drug development. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double stranded breaks in the DNA. About Beam TherapeuticsBeam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base-editing. All of the shares are being offered by Beam Therapeutics. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. See the full leadership team at Craft. Your browser will redirect to your requested content shortly. Cambridge, Mass. Only risk what you can afford to lose. Beam Therapeutics is developing precision genetic medicines through base editing. Share your opinion and gain insight from other stock traders and investors. Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Carole Ho, M.D., Chief Medical Officer and Head of Development at Denali Therapeutics, to the Company’s Board of Directors. John Evans, CEO of Beam Therapeutics. Beam CEO … She completed her medical internship and neurology residency at Harvard and served as Chief Resident of Neurology at the Massachusetts General Hospital / Brigham and Women’s Hospital. “I look forward to collaborating with John and the Beam team on this exciting approach for patients.”. [])). Find the latest Beam Therapeutics Inc. (BEAM) stock discussion in Yahoo Finance's forum. Please enable Cookies and reload the page. In addition, Beam Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. “The breadth and depth of her drug development expertise will be highly valuable to Beam as we advance the development of base editors as a new class of precision genetic medicines.”, “Base editing has the potential to correct point mutations and edit genes with high levels of precision and control, opening up new therapeutic strategies across many disease categories,” said Dr. Ho. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beam Therapeutics, are expected to be approximately $117.5 million excluding any exercise of the underwriters’ option to purchase additional shares. – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Carole Ho, M.D., Chief Medical Officer and Head of Development at Denali Therapeutics, to the Company’s Board of Directors. A registration statement relating to the shares being sold in this offering became effective by the Securities and Exchange Commission on September 30, 2020. Beam’s largest stockholders following the IPO are Arch Venture Partners, which owns 17 percent of Beam’s shares, and F-Prime Capital, which owns 14.4 percent. Prior to her current role as founding Chief Medical Officer and Head of Development at Denali Therapeutics, Dr. Ho served as Vice President of Early Clinical Development at Genentech. The offering is expected to close on October 5, 2020, subject to the satisfaction of customary closing conditions. During her eight-year tenure at Genentech, she held positions of increasing responsibility across both the early and late stage clinical development groups with development oversight for multiple therapeutic areas and molecules including crenezumab for Alzheimer’s disease, lampalizumab for dry age related macular degeneration, and development activities leading to the approvals of ocrelizumab for multiple sclerosis and Rituxan for Wegener’s granulomatosis and microscopic polyangiitis. Investors:Monique AllaireTHRUST Strategic Communicationsmonique@thrustsc.com, Use of this site indicates acceptance of the. This process is automatic. About Beam Therapeutics. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. “Carole has a remarkable track record in developing new medicines as well as in building and leading exceptional clinical development organizations,” said John Evans, CEO of Beam Therapeutics. The information on this Website is not reliable and not intended to provide tax, legal, or investment advice. RALEIGH — Beam Therapeutics, a Boston-based biotechnology company developing precision medicines through DNA base editing, plans to build … The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com; or Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: Barclaysprospectus@broadridge.com. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.